DIMERIX INVESTOR CALL & PRESENTATION

FSGS phase 3 study locations ACTION3 FSGS CLINICAL STUDY Global study with ~70 sites in 12 countries: Country Australia Argentina Brazil Regulatory and/or ethics approval to proceed A randomised, double-blind, multi-centre, placebo- controlled study of renal outcomes of DMX-200 in patients with primary FSGS receiving an ARB Denmark France Hong Kong New Zealand South Korea Spain Taiwan UK USA Dimerix 11

View entire presentation